Skip to main content
AUTL $1.14 -2.56%
AUTL logo
AUTL · Autolus Therapeutics plc
Track AUTL — free
$1.14 -0.03 (-2.56%) At close · Nov 16 Play latest call Q1 2026 earnings call transcript
Market Cap
$303.43M
Shares
266.16M
Volume · Nov 16 2.35M Avg daily vol (3M) 2.13M
All webcasts

Earnings call · FY2026 Q3

Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call

Concluded Nov 10, 2026
Nov 10, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $41.24M +94.6% YoY
Diluted EPS -$0.21
Gross margin · derived Q4 56.5% +91.6 pp YoY
Net income -$55.09M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 10, 2026
Autolus Therapeutics plc reported third-quarter AUCATZYL net product revenue of $41.2 million, up 95% year-over-year, and now expects 2026 revenue at or exceeding the upper end of $150 million.
10-Q report · filed Nov 10, 2026
Autolus Therapeutics reported AUCATZYL revenue of $41.2 million for the three months ended September 30, 2026, versus $21.1 million, as net loss narrowed to $55.1 million from $79.1 million. Cash and cash equivalents totaled $245.4 million.

The audio replay and transcript follow the call.

Forward guidance

2 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Nov 10, 2026.

Metric Guided
AUCATZYL net product revenue
full-year 2026
at least $150M
Gross profit margin
Peak
65% – 70%

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Product$41.24M +95% YoY
License$0 -100% YoY
Full-screen source Call document